Comparison of Specific Ovarian Tumor Markers by Elecsys Analyzer 2010

Lejla Hasanbegovic¹, Selma Alicelebic², Nedeljka Sljivo²

Biochemical-Immunological-Haematological “Medical Laboratory” Ilidza, Sarajevo, Bosnia and Herzegovina
Institute of Histology and Embryology, School of Medicine, Sarajevo, Bosnia and Herzegovina

ABSTRACT

Background: the most widely used tumor marker in ovarian cancer, often considered the ‘gold standard’ is CA125 but reliable clinical evidence demonstrates that human epididymis protein (HE4), used alone or in combination with CA125, substantially improves the accuracy of screening and/or disease monitoring. Aim: to evaluate the reliability of the determination a tumor marker HE4 in comparison with CA125 on the Elecsys analyzer 2010 in epithelial ovarian cancer, benign ovarian cyst and healthy controls. Methods: we prospectively determined CA125 and HE4 serum levels in the Biochemical-Immunological-Haematological “Medical Laboratory” Ilidza, Sarajevo, B&H between June 1st and December 31st 2011. Electro-chemiluminescence immunoassay (ECLIA) methods for quantitative determination in vitro were performed on the Roche/Hitachi Elecsys 2010 Immunoassay Analyzer. Standard methods of descriptive statistics were performed for the data analysis. Results: univariate statistical analyze of tumor marker control serum revealed a high reliability for both CA125 and HE4 determination (p<0.05). Levey-Jennings charts of quality control data show that the target and the obtained values of both markers control sera do not significantly differ in relation to the ideal value. In a total number of 60 patients compared values of tumor markers show a high correlation (r<0.85). This study confirmed higher sensitivity and specificity of HE4 tumor marker compared with CA125. ROC-AUC values show that the diagnostic performance of HE4 was significantly higher compared with CA125. Conclusion: We concluded that HE4 was better than CA125 as a single tumor marker.

Key words: ovarian tumor marker, CA125, HE4

1. INTRODUCTION

Noninvasive biomarker testing is essential for practical general population monitoring. Ovarian cancer is a lethal gynecologic malignancy with five-year survival of only 20% to 40% for advanced stage disease. Detection at an early stage would likely have significant impact on mortality rate. The most widely used tumor marker in ovarian cancer, often considered the ‘gold standard’ is CA125 (1). Measurement of CA125 can be performed with different commercial assays resulting in a certain degree of variation. Biomarker development efforts to date clearly indicate that no individual biomarker, including CA125, can provide sufficient sensitivity at high specificity for the early detection of ovarian cancer. CA125 can be elevated in a number of conditions unrelated to ovarian cancer, resulting in decreased specificity.

When values below 35 U/mL are designated as normal, CA125 is elevated in 80% of epithelial ovarian cancers (2). CA125 is elevated in approximately 50%-60% of stage I epithelial ovarian cancers and 75%-90% of patients with advanced stage disease (3, 4).

The sensitivity of CA125 to identify early stage disease is limited as a screening tool. The quest for other biomarker candidates has continued because a single CA125 value at a given time point will not reach a specificity of 99.6%, and approximately 20% of ovarian cancers may not express this antigen. Therefore, it is necessary to identify additional informative biomarkers that complement CA125. Reliable clinical evidence demonstrates that human epididymis protein (HE4), used alone or in combination with CA125, substantially improves the accuracy of screening and/or disease monitoring. HE4, found primarily in the epithelia of normal genital tissues is elevated in epithelial ovarian cancer (5,6). HE4 has greater specificity in the premenopausal age group than CA125 given it does not appear to be expressed at high levels in the setting of benign conditions (7-9).

In a systemic review of women with suspected gynecologic disease HE4 demonstrated a higher specificity (93% vs 78%) and similar sensitivity (79%) to CA125 when distinguishing benign disease from ovarian cancer (10).

Studies have demonstrated a potential benefit in combining HE4 and CA125 when quantifying risk potential malignancy in the evaluation of a pelvic mass (11, 12). Even with new technology, it is unlikely that an individual biomarker will reach a specificity of 99.6%, positive predictive value of 10%, and sensitivity greater than 75% when screening an asymptomatic general population.

It is important to measure the concentration of the tumor marker by the same method. Different antibodies, matrix and calibrator which are used in different methods may give different results. This means that different commercial tests give results for tumor markers that are not mutually comparable (13). The aim of this study was to evaluate the reliability of the determination a tumor marker HE4 in comparison with CA125 on the Elecsys analyzer 2010 in epithelial ovarian cancer, benign ovarian cyst and healthy controls.
2. PATIENTS AND METHODS

From June to December 2011, 60 patients were included in a prospective study conducted at the Biochemical-Immunological-Haematological "Medical Laboratory" Ilidza, Sarajevo, Bosnia and Herzegovina.

Study group (n=60) was consisted of 28 premenopausal and 32 postmenopausal patients which were previously diagnosed as some type of epithelial ovarian cancer (n=20), benign ovarian cyst (n=20) or were with normal woman's gynecological results (n=20).

Samples of venous blood were collected in serum gel tubes. After centrifugation and separation of serum, all samples were frozen until analysis. CA125 and HE4 serum levels were determined by Electro-chemiluminescence immunoassay (ECLIA) method for quantitative determination in vitro. Assays were performed on the Roche/Hitachi Elecsys 2010 Immunoassay Analyzer by Roche Diagnostics Ltd., Switzerland. All assays were run according to manufacturer’s instructions, and appropriate controls were within the ranges provided by the manufacturer for all runs.

The Elecsys CA 125 II tumor marker assay is based on the monoclonal M 11 and OC 125 antibodies from Fujirebio Diagnostics, Inc. Every Elecsys reagent set has a barcoded label containing specific information for calibration of the particular reagent lot. The predefined master curve is adapted to the analyzer using the relevant CalSet CA125 II. The measurement was performed by the generated voltage induced from chemi-luminescent emission of the photomultiplier. Values were expressed in units per milliliter (U/mL). Measuring range was from 0.600-5000 U/mL (defined by the lower detection limit and the maximum of the master curve). Test duration was 18 min. The reference value was <35 U/ml. Sensitivity (the minimum detectable dose of CA125) was determined to be 0.6 U/ml. Minimum detectable dose is defined as the analyte concentration resulting in an absorbance that is 2 standard deviations higher than that of the blank (diluted buffer). The following material was required for the analysis: the serum sample, Test Reagent CA125 II, CalSet CA125 II, PreciControl Tumor Marker1 (TM1) and PreciControl Tumor Marker2 (TM2), Diluent Universal, Procell and Cleancell.

The Elecsys Electro-chemiluminescence immunoassay (ECLIA) for the quantitative determination of human epididymal protein 4 (HE4) in serum and plasma assay is a two-step sandwich immunoassay. In this study two mouse monoclonal antibodies (2H5 and 3D8) directed against two epitopes in the C-WFDC domain of HE4 were used. First, sample was incubated with a biotinylated monoclonal HE4-specific antibody and a monoclonal HE4-specific antibody labeled with a ruthenium to forms a sandwich complex. After addition of streptavidin-coated microparticles, the complex bounds to the solid phase via interaction of biotin and streptavidin. The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed. A voltage is applied to the electrode to induce chemiluminescent emission which is measured by a photomultiplier. Test duration was 18 min. The results are determined via a calibration curve that is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent bar-code. Measuring range was from 15–1500 pmol/L. The serum sample, HE4 Test Reagent, HE4 CalSet, PreciControl HE4 Tumor Marker1 (TM1) and PreciControl HE4 Tumor Marker2 (TM2), Diluent Multi Assay, Procell and Cleancell.

All reagents were supplied by Roche Diagnostics Ltd. Target values and approximate target ranges of the reconstituted calibrators are presented in Table 1. and Table 2.:

| Control serum | Target range (value) U/mL |
|---------------|--------------------------|
| PreciControl TM1 – CA125 | 27.1 – 41.5 (34.3) |
| PreciControl TM2 – CA125 | 112 – 136 (124.00) |

Table 1. CA125–approximate target ranges and target values

| Control serum | Target range (value) pmol/L |
|---------------|----------------------------|
| PreciControl TM1 – HE4 | 32.9 – 51.2 (45.0) |
| PreciControl TM2–HE4 | 258 – 450 (354) |

Table 2. HE4–approximate target ranges and target values

The precision of the method was determined using twenty control serum samples for each PreciControl tumor marker. The results are summarized in the following Table 3.

| CA125U/mL | HE4 pmol/L |
|-----------|------------|
| TM1 | TM2 | TM1 | TM2 |
| 20 samples | 20 samples | 20 samples | 20 samples |
| Variance=0.3512 | Variance=0.1973 | Variance=0.1066 | Variance=0.1547 |
| SD=0.5926 | SD = 0.4442 | SD = 0.3266 | SD = 0.3934 |
| accept Normality (χ²=0.5285) | accept Normality (χ²=0.0307) | accept Normality (χ²=0.5256) | accept Normality (χ²=0.3625) |
| (df=2) | (df=2) | (df=2) | (df=2) |

Table 3. Chi-square Test for Normal Distribution of the investigated tumor markers determination methods precision

Statistical analysis was performed with SYSTAT 13.1 statistical software (Systat Software Inc., San Jose, California). Standard methods of descriptive statistics were performed for the data analysis. For the purposes of analysis in this study, the percentage of true positive (TP), true negative (TN), false positive (FP) and false negative results (FN), standard deviation, sensitivity (TP/TP+FN), specificity (TN/FP+TN) were used to evaluate the diagnostic performance of both markers. The diagnostic performance was studied with ROC (Receiver Operating Characteristic) curves based on continuous variables. The area under curve (AUC), standard error (SEAU), and confidence interval (CIAUC) for AUC were calculated according to the nonparametric method of DeLong et al. (14). This method was used to compare AUCs considering the fact that measurements of HE4 and CA125 were done for the same objects (group of patients). The level of significance was taken as p<0.05.

3. RESULTS

Univariate statistical analyze of tumor marker control serum revealed a high reliability for both CA125 and HE4 determination (p<0.05). It was found that the method of determining on an Elecsys 2010 analyzer for both tests showed a satisfactory degree of reproducibility. Chi-square test for normal distribution showed accepting values in all control sera. Levey-Jennings charts of quality control data show that the target and the obtained values of both markers control sera do not differ significantly in relation to the ideal value (Figure 1–4).

ACTA INFORM MED. 2015 APR 23(2): 86-89 / ORIGINAL PAPER
Comparison of Specific Ovarian Tumor Markers by Elecsys Analyzer 2010

Patients with normal woman’s gynecological results
• each) of patients which were previously diagnosed as follows:
  • Patients with normal woman’s gynecological results (group I–control group)
  • Patients with some type of ovarian cancer (group II)
  • Patients with benign ovarian cyst (group III)

Table 4. Tumor marker range and mean values in studied groups

| Values | Group I | Group II | Group III |
|--------|---------|----------|-----------|
| CA125 U/mL | min-max (mean) | HE4 pmol/L | min-max (mean) |
| Normal | 20/20 (100%) | 8/20 (40%) | 1/20 (5%) | 15/20 (75%) | 20/20 (100%) |  |
| Borderline | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) | 0/20 (0%) |  |
| High | 0/20 (0%) | 12/20 (60%) | 19/20 (95%) | 0/20 (0%) | 0/20 (0%) |  |

Table 5. Comparison of the tumor markers CA125 and HE4 values in the studied groups

This study confirmed higher sensitivity and specificity of HE4 tumor marker compared with CA125 (Table 6).

Table 6. Comparison of CA125 and HE4 tumor marker diagnostic performance

| Tumor marker | CA125 | HE4 |
|--------------|-------|-----|
| Test character-
istics: | Prevalence | Sensitivity | Specificity | Positive predictive value | Negative predictive value |
| CA125 | 12/10000 = 0.0012 (0.12%) | 12/20 = 0.65 (60%) | 48/40 = 0.851 (83.33%) | 12/60 = 0.2 (20%) | 48/60 = 0.8 (80%) |
| HE4 | 0.466 (0.2401-0.6414) | 0.71 (0.60-0.82) | 0.672 (0.5193-0.837) | 0.93 (0.86-0.97) | 0.683 (68.3%) |

Table 7. AUC (95% CI) values of studied tumor markers in premenopausal and postmenopausal patients

AUC (Area Under Curve) values, determined by ROC characteristics, show that the diagnostic performance tumor

Compared values of investigated patients tumor markers show a high correlation (r=0.85).

Study group (n=60) was consisted of three groups (n=20 each) of patients which were previously diagnosed as follows:
• Patients with normal woman’s gynecological results (group I–control group)
• Patients with some type of ovarian cancer (group II)
• Patients with benign ovarian cyst (group III)

Table 4. show range and mean values of tumor markers in investigated groups of patients.

Figure 1. Levey-Jennings chart of TM1 CA125 test

Legend: X; X+1SD; X+2SD; X-1SD; X-2SD

Figure 2. Levey-Jennings chart of TM2 CA125 test

Legend: X; X+1SD; X+2SD; X-1SD; X-2SD

Figure 3. Levey-Jennings chart of TM1 HE4 test

Legend: X; X+1SD; X+2SD; X-1SD; X-2SD

Figure 4. Levey-Jennings chart of TM2 HE4 test

Legend: X; X+1SD; X+2SD; X-1SD; X-2SD
marker HE4 was significantly higher than the tumor marker CA125 in both premenopausal and postmenopausal patients (Table 7).

4. DISCUSSION

With the exception of highly invasive procedures such as biopsy and surgery, the evaluation of circulating biomarkers offers the most definitive means of distinguishing benign from malignant cases. Several recent studies have evaluated various panels of circulating biomarkers in ovarian cancer patients and benign cases. Our study aimed to investigate the performance of serum tumour markers CA125 and HE4. Based on the obtained values of tumor markers and the actual condition in the test group, we determined the diagnostic value of both tumor markers. Sensitivity of CA125 was 60% with specificity of 83.33%, which was significantly less than the sensitivity of HE4 of 95% and its specificity of 97.5%. Positive predictive value of CA125 was 20%, while 31.7% of the HE4. The negative predictive value of tumor marker CA125 was 80%, versus 68.3% of the HE4. Our study confirmed that the sensitivity and specificity of HE4 were significantly higher than the CA125 tumor marker \( p = 0.047 \) which is consistent with research of Nolen and colleagues (11). Because of false positive CA125 values in benign gynecological tumors Moore et al (2008) also measured the serum levels of HE4, to increase the sensitivity and specificity of the diagnosis of this disease. They concluded that HE4 was better single marker to detect disease at an early stage, and that the parallel monitoring of both markers can better assess the risk of malignancy and may provide valuable information in distinguishing ovarian cancer from endometrioid cysts (12). Park et al. (15, 16) compared diagnostic performance of CA125 and HE4 in various gynecologic and non-gynecologic diseases. Their conclusions were: HE4 demonstrated comparable diagnostic performances to CA125, though each marker had its own strengths and weaknesses and combining CA125 and HE4 might be more advantageous than either one alone. The sensitivities and specificities of CA 125 and HE4 observed in our study are very similar to those observed by Moore et al. (12, 17), as is the observation that the two biomarkers display diagnostic complementation as each improves upon the discriminatory power of the other.

5. CONCLUSION

In our study, the ROC-AUC values for CA125 were significantly lower compared with HE4, suggesting a significantly higher performance of HE4 and we concluded that HE4 was better than CA125 as a single tumor marker. In summary, our validation study was able to demonstrate similar performance indices as those recently published in the literature.

CONFLICT OF INTEREST: NONE DECLARED.

REFERENCES

1. Hogdall E: Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol. 2008; 20: 4-8.
2. Cramer DW, O’Rourke DJ, Vitonis AF, Matulonis UA, Dijohnson DA, Sluss PM, Crum CP, Liu BC. CA125 immune complexes in ovarian cancer patients with low CA125 concentrations. Clin Chem. 2010; 56: 1889-1892.
3. Jacobs I, Bast RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989; 4: 1-12.
4. Woolas RP, Xu FJ, Jacobs IJ, Yu YJ, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC Jr. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 1993; 85: 1748-1751.
5. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, Macdonald N, Dawnyay A, Jeyarajah A, Bast RC, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol. 2005; 23: 7919-7926.
6. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellström KE. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003; 63: 3695-3700.
7. Moore RG, MacLaughlan S, Bast RC. Current state of bio-marker development for clinical application in epithelial ovarian cancer. Gynecol Oncol. 2010; 116: 240-245.
8. Huhtinen K, Suvitie P, Hiisa J, Junnila J, Huvila J, Kujari H, Setälä M, Härtki P, Jalkanen J, Fraser J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009; 100: 1315-1319.
9. Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast RC. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012; 206: 351.e1-351.e8.
10. Ferraro S, Fraga B, Lanzoni M, Baracchi P, Biganzoli EM, Pan teghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Pathol. 2013; 66: 273-281.
11. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC, Lokshin A. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010; 117: 440-445.
12. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008; 108: 402-408.
13. Chan DW, Booth RA, Diamandis EP. Tumormarkers. In: Burtis CA, Ashwood ER, Bruns DE, Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier Saunders, 2006: 745-795.
14. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the Areas Under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach. Biometrics. 1988; 44: 837-845.
15. Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011; 44(10-11): 884-888.
16. Park Y, Kim Y, Lee EY, Lee JH, Kim HS. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer. 2012; 130(5): 1136-1144.
17. Moore RG, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009; 112(1): 40-46.